Ovid Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $4.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ram Selvaraju has given his Buy rating due to a combination of factors, notably Ovid’s advancing KCC2 platform and the upcoming Deep Dive R&D event that should clarify the scientific and commercial potential of this first-in-class franchise. He views the company’s differentiated KCC2 activators, including IV and oral candidates with broad applicability across neurological and neuropsychiatric diseases, as a meaningful strategic asset that is not yet fully reflected in current valuation.
He also highlights the imminent clinical entry of OV4071, the first oral KCC2 direct activator, supported by recent regulatory clearance that triggers time‑bound warrant exercises and underscores investor commitment. Finally, because his valuation model currently assigns no explicit contribution from the KCC2 portfolio, he sees any positive clinical progress with OV4071 or follow‑on candidates as a source of material upside to both forecasts and price target, reinforcing the Buy recommendation.
In another report released yesterday, TipRanks – PerPlexity also upgraded the stock to a Buy with a $3.00 price target.